Merck Sharp & Dohme publishes application on stable PD-1 antibody and hyaluronidase formulations.
The filing
Merck Sharp & Dohme published an application on November 12, 2026, for stable formulations of PD-1 antibodies and hyaluronidase variants and fragments. The application is available at US20260356952A1 (opens in a new tab).
This filing’s full text wasn’t read for this issue, so its claims and the applicant’s background aren’t shown. Both are in the record, under Sources.